A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
Call us @: 844 663-3742
Study Details
Medical Condition
Study Phase
Intervention Type
Date
Participation Requirements
Gender
Age
Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Have a question?
You can ask us questions via online form or phone call.
Call us @: 844 663-3742
| Location | Status | Site Contact Details |
|---|
This is a 3 part phase 1 study to evaluate the safety, pharmacokinetic and oral bioavailability of veliparib in subjects with solid tumors.
Part 2 - Dose Escalation Cohort: Pharmacokinetic testing
Time Frame: Up to 36 months
Part 1 - Pharmacokinetic profile
Time Frame: Up to Day 6
Part 3 - Safety Expanded Cohort: Number of subjects with adverse events
Time Frame: Up to 36 months
Part 3 - Safety Expanded Cohort: Vital signs
Time Frame: Up to 36 months
Part 3 - Safety Expanded Cohort: Laboratory tests
Time Frame: Up to 36 months
The number of participants with adverse events who receive the extended release formulations of veliparib.
Time Frame: Up to 36 months
Interventions:
- Drug: Veliparib
- Drug: Veliparib
- Drug: Veliparib
Enrollment:
71
Additional Information
Watch a video to learn more about what you may experience as a clinical trial volunteer: /resources/what-happens-in-a-clinical-trial
Take a virtual reality screening visit tour to an example of a clinical trial site: /resources/screening-visit-virtual-tour
Use a questionnaire tool to think through questions to ask yourself about participating in a clinical trial and print out your responses to discuss with your partners in your health journey: /resource-information-clinical-trial-community/decision-counselor